Nikita Urval, MD
Neurology · Butler, PANPI 1194112821
Payments from drug & device makers
Across 357 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amneal Pharmaceuticals LLC$565
- UCB, Inc.$479
- MDD US Operations, LLC$451
- Eisai Inc.$436
- Teva Pharmaceuticals USA, Inc.$434
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$180%
- Food & beverage$7,31597%
- Education$2103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,552 |
| Amneal Pharmaceuticals LLC | 28 | $565 |
| UCB, Inc. | 25 | $479 |
| MDD US Operations, LLC | 20 | $451 |
| Eisai Inc. | 26 | $436 |
| Teva Pharmaceuticals USA, Inc. | 19 | $434 |
| Ipsen Biopharmaceuticals, Inc | 7 | $299 |
| Boston Scientific | 4 | $274 |
| Pfizer | 18 | $272 |
| Lundbeck LLC | 9 | $231 |
| Acadia Pharmaceuticals Inc | 15 | $230 |
| Novartis | 11 | $223 |
| Abbott | 4 | $210 |
| Kyowa Kirin, Inc. | 4 | $194 |
| Lilly USA, LLC | 9 | $182 |
| Medtronic | 3 | $179 |
| Neurocrine Biosciences, Inc. | 7 | $178 |
| EMD Serono, Inc. | 3 | $170 |
| Merz Pharmaceuticals, LLC | 6 | $156 |
| SK Life Science, Inc. | 5 | $109 |
| Argenx US, Inc. | 5 | $98 |
| Genentech USA, Inc. | 4 | $86 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| E.r. Squibb & Sons, L.L.C. | 1 | $52 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| Neurelis, Inc. | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Biogen | 2 | $37 |
| Bristol Myers Squibb | 2 | $31 |
| Tanabe Pharma America, Inc. | 2 | $29 |
| Sanofi | 1 | $22 |
| Amgen | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Avion Pharmaceuticals | 1 | $19 |
| CSL Behring | 1 | $15 |
| Impel Pharmaceuticals LLC | 1 | $14 |
| Livanova USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$357
- UBRELVY$357
- GENERAL DBS$136
- NOURIANZ$135
- RYTARY$125
- Briviact$125
- DYSPORT$124
- Leqembi$121
- PERCEPT PC BRAINSENSE$120
- VYEPTI$116
- Mavenclad$114
- Infinity DBS Pulse Generators$111
How this compares
$7,544 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 15 | $121,316 |
| RytaryCarbidopa/Levodopa | 156 | $99,491 |
| BriviactBrivaracetam | 25 | $35,262 |
| BotoxOnabotulinumtoxina | 27 | $32,725 |
| NourianzIstradefylline | 11 | $23,360 |
| UbrelvyUbrogepant | 14 | $18,325 |
| Rasagiline Mesylate | 125 | $17,754 |
| QuliptaAtogepant | 12 | $16,082 |
| Rivastigmine | 124 | $14,424 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 439 | $13,222 |
| MyrbetriqMirabegron | 23 | $10,021 |
| GemtesaVibegron | 19 | $8,998 |
| CrexontCarbidopa/Levodopa | 14 | $7,937 |
| Pyridostigmine Bromide | 26 | $3,923 |
| Gabapentin | 248 | $3,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $178 | $121,31615 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont, Pyridostigmine Bromide | $565 | $111,351196 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $1,552 | $67,13253 claims |
| UCB, Inc.Briviact | $479 | $35,26225 claims |
| Kyowa Kirin, Inc.Nourianz | $194 | $23,36011 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $20 | $8,99819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Butler
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.